PMAM
MRSN

Picton Mahoney Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Picton Mahoney Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-115
Closed -$4K – 987
2024
Q4 		$4K Buy
115
+15
+15% +$776 ﹤0.01% 575
2024
Q3 		$4K Buy
100
+73
+270% +$3.22K ﹤0.01% 550
2024
Q2 		$1K Buy
+27
New +$1.95K ﹤0.01% 579

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Picton Mahoney Asset Management's MRSN Position: Q1 2025 in Review

Picton Mahoney Asset Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 115 shares — an estimated $4K sold.

Picton Mahoney Asset Management first reported a position in MRSN in Q2 2024 and held it in 3 quarters. The position peaked at $4K in Q4 2024. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Picton Mahoney Asset Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 115 Mersana Therapeutics shares in Q1 2025, an estimated $4K.
  • Picton Mahoney Asset Management first reported a position in Mersana Therapeutics in Q2 2024 and held it in 3 quarters.
  • Picton Mahoney Asset Management's Mersana Therapeutics position peaked at $4K in Q4 2024.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2025, filed 7 May 2025.